Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: AVEO Pharmaceuticals
So what: AVEO is selling 5.8 million shares for $17.50 per share, an 8% discount to Tuesday's closing price of $19.09. The underwriters will have an option to buy up to 863,000 additional shares to cover any overallotments. The secondary offering should raise about $100 million before discounts and expenses.
Now what: The secondary offering will boost the share count -- and dilute EPS -- by 16% to 19%. In February, AVEO announced a partnership with Japanese drugmaker Astellas, under which AVEO received $125 million upfront and has the potential to receive another $1.3 billion for achieving milestones. Absent the Astellas deal, AVEO has been losing money and burning cash. With $233 billion in cash on the balance sheet and anticipated milestone payments, the need to raise roughly $100 million more suggests substantial product revenue and profits could take longer than previously anticipated.
Interested in more info on AVEO? Add it to your watchlist by clicking here.
Fool contributor Cindy Johnson does not own shares of any company named above. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Here's Why AVEO Oncology Rose as Much as 13.7% Today
The company is fresh off a presentation at the J,P. Morgan Healthcare Conference.
Why AVEO Pharmaceuticals, Inc. Tanked 18.6% in October
The wild ride continues.
3 Biotech Stocks That Turned $1,000 Into More Than $5,000 This Year
These three biotech stocks helped a lot of investors get rich this year. Are there more gains ahead?